Midterm Flashcards
examples of primary prevention
immunizations or behavioral counseling to remove risk factors
examples of secondary prevention
screening, early detection, and treatment
examples of tertiary prevention
treatment focused on long-term outcomes and prevention of disease progression and complications
secondary prevention in cardiology
patients have known disease and are being treated or are at very high risk of disease
secondary prevention in neurology
patients who have had a stroke or TIA or who are at very high risk of ischemic stroke
primum non nocere
first, do no harm - nonmaleficence
3 major aspects to consider when screening
the burden of disease, the sensitivity/specificity of the screening test, and the efficacy of treatment
sensitivity
the probability that a patient with the disease will have a positive test (SNOUT) - high sensitivity rules out disease
specificity
the probability that a patient without the disease will test negative (SPIN) - high specificity rules in disease
positive predictive value
likelihood that a person with a positive test has the disease - dependent on prevalence
negative predictive value
likelihood that a person with a negative test does not have the disease - dependent on prevalence
which predictive value is more useful with a low prevalence of disease?
negative predictive value (rules out disease)
predictive value of most screening tests
high negative predictive value
lead time bias
people who are diagnosed with screening survive longer after diagnosis than patients who present with symptoms even if treatment does not make a difference
length time bias
slower-growing cancers are more likely to be found by screening whereas faster-growing cancers usually present between screenings or before it starts
compliance bias
compliant patients have a better prognosis than non-compliant patients regardless of screening
external validity
generalizability - how well the study applies to patients who were not in the study
USPSTF
created in 1984 and make evidence-based recommendations about clinical preventative services excluding vaccines (does not consider cost of services)
CDC
advisory committee on immunization practices
CDC recommends Td/Tdap
a single dose of Tdap in place of Td for all adults age 19+ who have not received Tdap previously followed by Td booster every 10 years
CDC recommends Zoster (Shingles) vaccine
in adults age 50+
CDC recommends MMR vaccine
1-2 doses if born in 1957 or later
CDC recommends Varicella vaccine
age 13+ without evidence of immunity (history chickenpox)
CDC recommends HPV vaccine
in females up to age 26 (or up to age 45 with shared decision making), in males up to age 21, and in men who have sex with men (MSM) up to age 26